Quick Answer
Arcutis Biotherapeutics, Inc. reported Earnings Per Share Diluted of $0.13 (loss) per share for the year ending 2025.
- Arcutis Biotherapeutics, Inc. showed an increase of +88.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Arcutis Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $0.94 (loss) per share | Q3 2020: $1.01 (loss) per share | Q1 2021: $0.76 (loss) per share | Q2 2021: $0.84 (loss) per share | Q3 2021: $1.14 (loss) per share | Q1 2022: $1.27 (loss) per share | Q2 2022: $1.31 (loss) per share | Q3 2022: $1.89 (loss) per share | Q1 2023: $1.31 (loss) per share | Q2 2023: $1.16 (loss) per share | Q3 2023: $0.73 (loss) per share | Q1 2024: $0.32 (loss) per share | Q2 2024: $0.42 (loss) per share | Q3 2024: $0.33 (loss) per share | Q1 2025: $0.20 (loss) per share | Q2 2025: $0.13 (loss) per share | Q3 2025: $0.06 per share.
- Over the full 7 years of available data (2019 to 2025), Arcutis Biotherapeutics, Inc.'s Earnings Per Share Diluted has grown by 99.4%.
- Historical annual values: Fiscal year 2025: $0.13 (loss) per share | Fiscal year 2024: $1.16 (loss) per share | Fiscal year 2023: $3.78 (loss) per share | Fiscal year 2022: $5.66 (loss) per share | Fiscal year 2021: $4.18 (loss) per share | Fiscal year 2020: $3.80 (loss) per share | Fiscal year 2019: $22.78 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: